Alzheimer's Disease and Dementia

Alzheimer's disease is the most common cause of dementia, accounting for an estimated 60 to 80 percent of dementia cases according to the Alzheimer's Association. This page covers the clinical definition of dementia and its subtypes, the underlying neurobiological mechanisms of Alzheimer's disease, the settings in which diagnosis and management typically occur, and the boundaries that distinguish normal aging from pathological cognitive decline. Understanding these distinctions matters for informed navigation of neurological care, particularly given the regulatory and public health frameworks that govern dementia diagnosis and treatment in the United States. For a broader orientation to the site's neurological topics, see the main index.

Definition and Scope

Dementia is not a single disease but a clinical syndrome defined by progressive deterioration in at least two cognitive domains — such as memory, language, executive function, visuospatial ability, or personality — severe enough to interfere with daily functioning. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), published by the American Psychiatric Association, reclassified dementia under the term Major Neurocognitive Disorder, though "dementia" remains in widespread clinical and regulatory use.

Alzheimer's disease is classified as a neurodegenerative dementia. Other recognized dementia subtypes include:

Vascular dementia — caused by cerebrovascular disease, including stroke and small vessel ischemia; the second most common subtype
Lewy body dementia (LBD) — characterized by abnormal alpha-synuclein protein deposits and associated with visual hallucinations and Parkinsonism
Frontotemporal dementia (FTD) — encompasses Pick's disease and related syndromes; disproportionately affects behavior and language before memory
Mixed dementia — coexisting Alzheimer's pathology and vascular or Lewy body changes, documented in a substantial proportion of autopsy studies
Parkinson's disease dementia — motor symptoms precede cognitive decline by at least one year, distinguishing it from LBD

The National Institute on Aging (NIA) maintains the primary federal research and classification framework for Alzheimer's disease and related dementias (ADRD), a term used in federal funding and policy to encompass all dementia subtypes.

How It Works

Alzheimer's disease involves two defining neuropathological hallmarks identified through postmortem examination and, more recently, through biomarker testing during life:

Amyloid plaques — extracellular deposits of beta-amyloid peptide fragments that aggregate between neurons
Neurofibrillary tangles — intracellular accumulations of hyperphosphorylated tau protein that disrupt neuronal transport and function

These abnormalities propagate across the brain in a predictable anatomical sequence. Tau pathology typically begins in the entorhinal cortex and hippocampus — regions central to memory consolidation — before spreading to association cortices. The National Institute of Neurological Disorders and Stroke (NINDS) identifies hippocampal atrophy as the earliest structural change detectable on MRI in most patients.

Amyloid accumulation is believed to precede clinical symptoms by 15 to 20 years, a timeline supported by longitudinal data from the Alzheimer's Disease Neuroimaging Initiative (ADNI). This extended preclinical phase has driven development of blood-based biomarkers, including plasma phospho-tau 217, as early detection tools.

Neuronal loss triggers deficits in acetylcholine neurotransmission, the mechanism targeted by the first approved pharmacological class: cholinesterase inhibitors (donepezil, rivastigmine, galantamine). The U.S. Food and Drug Administration (FDA) has also approved memantine, an NMDA receptor antagonist, for moderate-to-severe stages, and — after considerable regulatory debate — the anti-amyloid monoclonal antibodies lecanemab (Leqembi) and donanemab, the latter receiving full FDA approval in 2024.

Common Scenarios

Dementia evaluation enters clinical practice across four primary settings:

Primary care referral — A patient's family physician documents progressive memory complaints over 6 to 12 months, administers a brief cognitive screening tool such as the Montreal Cognitive Assessment (MoCA) or the Mini-Mental State Examination (MMSE), and refers to neurology when screening scores fall below established thresholds. Differentiating memory loss beyond normal aging from early Alzheimer's disease is a central diagnostic task at this stage.

Neurological specialty evaluation — A neurologist conducts a comprehensive neurological examination and may order MRI brain imaging, neuropsychological testing, and cerebrospinal fluid biomarkers via lumbar puncture to confirm diagnosis and subtype.

Memory disorder clinic — Tertiary academic centers operate dedicated dementia programs where multidisciplinary teams — neurology, neuropsychology, social work, and geriatric psychiatry — coordinate diagnosis, staging, clinical trial enrollment, and care planning.

Caregiver-initiated evaluation — Behavioral changes such as aggression, wandering, or loss of activities of daily living prompt care settings — assisted living, memory care units — to request formal cognitive reassessment. Resources for those supporting a patient are addressed separately at caring for someone with dementia.

Medicare's Annual Wellness Visit includes cognitive assessment as a covered preventive service under the Centers for Medicare & Medicaid Services (CMS), establishing a regulatory pathway for structured detection in primary care.

Decision Boundaries

Clinicians apply structured criteria to distinguish among dementia subtypes and to separate dementia from milder cognitive states. The NIA-AA Research Framework (2018) defines Alzheimer's disease biologically using an A/T/N classification — Amyloid, Tau, Neurodegeneration — decoupling diagnosis from clinical stage.

Key clinical boundaries:

Normal aging vs. Mild Cognitive Impairment (MCI) — MCI requires objective cognitive impairment on testing with preserved functional independence. Not all MCI progresses to dementia; conversion rates to Alzheimer's dementia average approximately 10 to 15 percent per year in clinic-based samples (NIA).
MCI vs. Major Neurocognitive Disorder (dementia) — The threshold is functional impairment. When deficits prevent independent management of finances, medications, or transportation, the DSM-5 criteria for Major Neurocognitive Disorder are met.
Alzheimer's vs. Lewy body dementia — LBD is distinguished by the presence of at least two of four core features: fluctuating cognition, recurrent visual hallucinations, REM sleep behavior disorder, and spontaneous Parkinsonism, per criteria established by the DLB Consortium.
Alzheimer's vs. Frontotemporal dementia — FTD onset before age 65 is more common than Alzheimer's in that age bracket; behavioral variant FTD affects frontal and temporal lobes with relative hippocampal sparing on imaging.

The regulatory context for neurological conditions covers how federal agencies govern dementia-related clinical trial oversight, drug approval pathways, and long-term care standards that apply to this patient population.

Staging in clinical and research practice follows either the Global Deterioration Scale (GDS) or the Clinical Dementia Rating (CDR) instrument, both of which assign severity on a 0–3 (CDR) or 1–7 (GDS) ordinal scale. Staging guides treatment selection, care planning, and determination of clinical trial eligibility.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)